 |
|
| Genetics |
|
| • |
ABL Kinase Domain Mutation in CML |
| • |
ABL T315I Mutation in CML |
| • |
Acetylcholinesterase |
| • |
Acylcarnitine, Plasma |
| • |
Alpha Fetoprotein
(AFP) |
| • |
Amino Acid Analysis |
| • |
AML1/ETO
t(8;21) Quantitative Real-Time-PCR |
| • |
Ashkenazi Jewish Panel |
| • |
B-Cell Gene Rearrangement, PCR |
| • |
B-Cell, Patient-specific Monitoring |
| • |
bcr/abl
Gene Rearrangement, Quantitative PCR |
| • |
Biotinidase
Deficiency |
| • |
Bloom Syndrome DNA Mutation Analysis |
| • |
Breast Cancer Gene Expression Ratio (HOXB13:IL17BR) |
| • |
CAH (21-Hydroxylase Deficiency) Common Mutations |
| • |
CAH (21-Hydroxylase Deficiency) Rare Mutations |
| • |
CAH
Panel 1 (21-Hydroxylase vs 11β-Hydroxylase Deficiency) |
| • |
CAH
Panel 3 (Aldosterone Synthase Deficiency) |
| • |
CAH
Panel 4 (17-Hydroxylase Deficiency in Females) |
| • |
CAH
Panel 6 (StAR Deficiency) |
| • |
CAH
Panel 6B (Comprehensive Screen) |
| • |
CAH
Panel 7 (21-Hyroxylase Deficiency Therapeutic Monitoring) |
| • |
CAH
Panel 8 (17-Hydroxylase Deficiency in Males) |
| • |
CAH
Panel 9 (3β-Hydroxysteroid Dehydrogenase Deficiency) |
| • |
CAH
Panel 11, Neonatal Random Urine |
| • |
Canavan
Disease Mutation Analysis |
| • |
Carnitine, LC/MS/MS |
| • |
CBFB/MYH11
inv(16), Quantitative Real-time PCR |
| • |
Chromosome
Analysis |
| • |
Chronic Lymphocytic Leukemia IgVh Mutation
Status |
| • |
c-kit Mutation Analysis, Plasma-based, Leumeta™ |
| • |
CLL Prognostic Panel |
| • |
Cystic
Fibrosis CFTR Gene Deletion or Duplication |
| • |
Cystic
Fibrosis CFTR
Intron 8 Poly-T Analysis |
| • |
Cystic Fibrosis Complete |
| • |
Cystic
Fibrosis D1152H Mutation Analysis |
| • |
Cystic
Fibrosis DNA Analysis, Fetus |
| • |
Cystic
Fibrosis Rare Mutation Analysis, One Exon |
| • |
Cystic
Fibrosis Rare Mutation Analysis, Two Exon |
| • |
Cystic
Fibrosis Screen |
| • |
Cytochrome P450 2C9
Genotype |
| • |
Cytochrome P450 2C9 and VK0RC1 Mutation Analysis |
| • |
Delta Aminolevulinic Acid |
| • |
Dihydropyrimidine Dehydrogenase (DPYD) Gene Mutation Analysis |
| • |
EGFR
Pathway (KRAS with Reflex to NRAS, BRAF) |
| • |
Factor V HR2 Allele DNA Mutation Analysis |
| • |
Factor
V (Leiden) Mutation Analysis |
| • |
Familial
Dysautonomia Mutation Analysis |
| • |
Fanconi
Anemia DNA Mutation Analysis |
| • |
Fetal
Hemoglobin |
| • |
FIP1L1-PDGFRA Gene Rearrangement [del (4q12)], Real-time PCR |
| • |
First
Trimester Screen, hCG |
| • |
First
Trimester Screen, Hyperglycosylated hCG (h-hCG) |
| • |
FISH, ALCL, ALK, 2p23 Rearrangements |
| • |
FISH, ALL, +4, +10, +17 |
| • |
FISH, ALL, Extended Panel |
| • |
FISH, ALL, Pre-B Panel |
| • |
FISH, ALL, TEL/AML1, Translocation 12;21 |
| • |
FISH, ALL/NHL, MYC-BA, 8q24 Rearrangement |
| • |
FISH, Angelman |
| • |
FISH, B-Cell Chronic Lymphocytic Leukemia (B-CLL) Panel |
| • |
FISH, B-Cell Malignancy, IGH, 14q32 Rearrangement |
| • |
FISH, Burkitt’s/NHL/ALL, IGH/MYC, t(8;14) |
| • |
FISH, Chromosome 20q Deletion |
| • |
FISH, CML/ALL, bcr/abl Translocation 9;22
|
| • |
FISH, Cri du chat |
| • |
FISH, DiGeorge, Velocardiofacial (VCFS) |
| • |
FISH, Follicular Lymphoma, IGH/BCL2, t(14;18) |
| • |
FISH,
HER-2/neu, Paraffin Block |
| • |
FISH, MALT Lymphoma, AP12/MALT1, t(11;18) |
| • |
FISH, MALT Lymphoma, MALT1, 18q21 Rearrangement |
| • |
FISH, MALT Lymphoma, MALT1, rea18q21 with Reflex to AP12/MALT1,
t(11;18) |
| • |
FISH, Mantle Cell Lymphoma, IGH/CCND1, t(11;14) |
| • |
FISH, Microdeletion Syndromes Panel |
| • |
FISH, Miller-Dieker |
| • |
FISH, Myeloid Disorders Profile |
| • |
FISH, Neonatal Screen |
| • |
FISH, SKY®′ Marker Chromosome |
| • |
FISH, Smith-Magenis |
| • |
FISH, Subtelomere Screen |
| • |
FISH,
Vysis®′ UroVysion™′, Bladder Cancer |
| • |
FISH, Wolf-Hirschhorn |
| • |
Follicular Lymphoma, bcl-2/JH t(14;18), Real-time PCR, Cell-based |
| • |
Gaucher Disease, DNA Mutation Analysis |
| • |
Genomic Alterations, Postnatal, ClariSure™ CGH |
| • |
HLA Typing for Celiac Disease |
| • |
Homocysteine |
| • |
Human
Chorionic Gonadotropin (hCG) |
| • |
Hyperglycosylated hCG |
| • |
Inhibin
A |
| • |
Integrated
Screening |
| • |
JAK2 and MPL
Mutation Analysis |
| • |
KRAS Mutation Analysis |
| • |
Mantle Cell Lymphoma, bcl-1/JH t(11;14), Real-time PCR, Cell-based |
| • |
Maple Syrup Disease (MSUD) Mutation Analysis
(Ashkenazi Jewish) |
| • |
MEN 2 and FMTC Mutations, Exons 10, 11, and 13-16 |
| • |
Methylenetetrahydrofolate
Reductase (MTHFR) DNA Mutation Analysis |
| • |
Methylmalonic Acid |
| • |
Microsatellite
Instability (MSI), HNPCC |
| • |
MLH1, MSH2, and MSH6 Mutations for HNPCC |
| • |
Niemann-Pick Disease Mutation Analysis |
| • |
Organic Acids |
| • |
Penta Screen |
| • |
Phenylalanine |
| • |
PML/RARA t(15;17), Quantitative PCR |
| • |
Porphobilinogen,
Quantitative |
| • |
Porphyrins,
Fractionated |
| • |
Porphyrins,
Total |
| • |
Prader-Willi/Angelman Syndrome |
| • |
Pregnancy-associated Plasma Protein A (PAPP-A) |
|
• |
Prothrombin (Factor II) 20210G→A Mutation Analysis |
| • |
Quad Screen |
| • |
Rett Syndrome Mutation Analysis |
| • |
Tay-Sachs Disease Mutation Analysis |
| • |
T-Cell
Receptor (TCR) Gene Rearrangement |
| • |
TPMT Genotype |
| • |
Tryptophan, LC/MS |
| • |
Tyrosine |
| • |
UGT1A1 Gene Polymorphism (TA Repeat) |
| • |
Unconjugated
Estriol (uE3) |
| • |
XSense,™ Fragile X with Reflex |